Drugs / IOV-5001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07743723 | Sep 2026 → Mar 2034 expected | colorectal cancer, head and neck squamous cell carcinoma, metastatic malignant neoplasm, non-small cell lung carcinoma +1 | Iovance Biotherapeutics, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Iovance Biotherapeutics, Inc. | Regulatory Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001 iovance.com ↗
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced allowance to proceed from the U.S. Food and Drug Administration (FDA) for the investigational new drug (IND) application for a Phase 1/2 basket trial of IOV-5001, a next-generation interleukin-12 (IL-12) tethered TIL therapy. |
| 2026-05-07 | Iovance Biotherapeutics, Inc. | Regulatory Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates iovance.com ↗
An Investigational New Drug (IND) application was submitted to FDA for a Phase 1/2 basket trial of IOV-5001, a second-generation IL-12 tethered TIL therapy, to begin enrolling in 2H 2026. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Iovance Biotherapeutics, Inc. | Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001 iovance.com ↗ |
| 2026-05-07 | Iovance Biotherapeutics, Inc. | Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates iovance.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IOV-5001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07743723 ↗ |
| Action | Deplete | “directly target and kill the tumor cells” NCT07743723 ↗ |
| Modality | Cell therapy | “autologous tumor-infiltrating lymphocytes (TIL) regimen” NCT07743723 ↗ |